<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287287</url>
  </required_header>
  <id_info>
    <org_study_id>05-701-F3R</org_study_id>
    <nct_id>NCT00287287</nct_id>
    <nct_alias>NCT00381498</nct_alias>
  </id_info>
  <brief_title>REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas</brief_title>
  <official_title>Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary &amp; Follicular Thyroid Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth Ain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the anti-tumor activity of REVLIMID®&#xD;
      (lenalidomide), administered as a single agent, in patients with distantly metastatic thyroid&#xD;
      carcinomas which are unresponsive to systemic radioiodine, in terms of tumor response and&#xD;
      response duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide has found new uses as a tumor anti-angiogenesis agent that is capable of&#xD;
      diminishing the proliferation of angiogenesis-dependent solid malignancies. Distantly&#xD;
      metastatic, unresectable medullary thyroid carcinomas, as well as de-differentiated papillary&#xD;
      and follicular thyroid carcinomas, which no longer concentrate radioiodine, have no known&#xD;
      effective systemic therapies. We have verified, in the context of a completed phase 2&#xD;
      clinical trial, that thalidomide has significant activity in thyroid carcinomas that are no&#xD;
      longer radioiodine avid and are rapidly progressive. This activity has only limited&#xD;
      durability of around 7 months and is associated with significant toxicities of sedation,&#xD;
      constipation and neuropathy.&#xD;
&#xD;
      REVLIMID® (lenalidomide) is an analog of thalidomide with the chemical name,&#xD;
      alpha-(3-aminophthalimido) glutarimide. REVLIMID® is noted to be more potent than thalidomide&#xD;
      in inhibiting the production of TNF-alpha. It has more than doubled the inhibition of&#xD;
      microvessel growth at the same concentration as thalidomide in a rat aorta angiogenesis model&#xD;
      as well as greatly enhanced activity as an IMiD. Most importantly, it lacks much of the&#xD;
      toxicity of thalidomide, particularly in regards to somnolence, neuropathy, or biochemical&#xD;
      effects. In fact, patients with multiple myeloma, known to be resistant to thalidomide, were&#xD;
      still seen to exhibit clinical responses to REVLIMID®. This makes REVLIMID® an appropriate&#xD;
      agent to investigate in a phase 2 trial in thyroid carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2006</start_date>
  <completion_date type="Actual">July 6, 2010</completion_date>
  <primary_completion_date type="Actual">July 6, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 years</time_frame>
    <description>Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Lenalidomide (Revlimid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day</description>
    <arm_group_label>Lenalidomide (Revlimid)</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of follicular, papillary, insular, or Hürthle-cell thyroid&#xD;
             carcinoma. Histologic slides and/or tissue blocks must be reviewed at the University&#xD;
             of Kentucky Medical Center.&#xD;
&#xD;
          -  Patients must have an unresectable, distantly metastatic tumor, which does not&#xD;
             concentrate radioactive iodine. Alternatively, follicular or papillary thyroid&#xD;
             carcinoma patients with large distant tumor burdens which have not sufficiently&#xD;
             responded to more than 800 mCi I-131 cumulative therapy and are progressive (criteria&#xD;
             #4) may be appropriate for inclusion.&#xD;
&#xD;
          -  No systemic chemotherapy agents within 4 weeks of initiation of therapy.&#xD;
&#xD;
          -  Patients must have 3 consecutive radiographic evaluations demonstrating a cumulative&#xD;
             30% increase in tumor volume over a period of one year or less.&#xD;
&#xD;
          -  Patients must be over the age of 18 years with the ability to understand and willing&#xD;
             to sign an informed consent.&#xD;
&#xD;
          -  Non-pregnant (if female). Women of childbearing potential (fertile females) must have&#xD;
             a negative serum or urine pregnancy test within one day of starting study drug. In&#xD;
             addition, sexually active fertile female subjects must agree to adequate contraceptive&#xD;
             methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation,&#xD;
             intrauterine device, barrier contraceptive with spermicide; or vasectomized partner)&#xD;
             while on study drug. Men must agree to use latex condoms when having sex with fertile&#xD;
             women.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70.&#xD;
&#xD;
          -  Baseline laboratory studies:&#xD;
&#xD;
               -  absolute neutrophil count (ANC) &gt; 1000/mm3&#xD;
&#xD;
               -  platelet count ≥ 100 K/mm3&#xD;
&#xD;
               -  creatinine ≤ 1.5 mg/dL, and&#xD;
&#xD;
               -  transaminase levels (AST/SGOT, ALT/SGPT) ≤ 2 x upper limit of normal (ULN) (or ≤&#xD;
                  5 x I:M if hepatic metastases are present)&#xD;
&#xD;
          -  Disease free of other prior malignancies for ≥ 5 years, with the exception of&#xD;
             currently treated basal cell/squamous cell carcinoma of the skin or &quot;in-situ&quot;&#xD;
             carcinoma of the cervix or breast.&#xD;
&#xD;
          -  Thyroid stimulating hormone (TSH, thyrotropin) levels must be suppressed with&#xD;
             sufficient levothyroxine to be kept beneath the normal range of the assay.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not have had prior REVLIMID® therapy.&#xD;
&#xD;
          -  No serious concomitant medical or psychiatric illness that might interfere with&#xD;
             informed consent or conduct of the study, including active infections that are not&#xD;
             controlled with medication.&#xD;
&#xD;
          -  Patients must not be pregnant or breastfeeding.&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of baseline.&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide.&#xD;
&#xD;
          -  The development of erythema nodosum, characterized by a desquamating rash, while&#xD;
             taking thalidomide or similar drugs.&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or treatments, with the exception of&#xD;
             thyrotropin-suppression by levothyroxine.&#xD;
&#xD;
          -  All subjects with central nervous system involvement, with the exception of those&#xD;
             subjects whose central nervous system metastases have been treated with either&#xD;
             radiotherapy and/or surgery and remain asymptomatic with no evidence of active central&#xD;
             nervous system disease (verified by computed tomography [CT] scan or magnetic&#xD;
             resonance imaging [MRI]) for at least 6 months.&#xD;
&#xD;
          -  Known to be positive for HIV or infectious hepatitis, type A, B, or C.&#xD;
&#xD;
          -  Patients with medullary or anaplastic thyroid carcinomas are excluded. Patients whose&#xD;
             disease is limited to bone metastases are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth B Ain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <results_first_submitted>May 28, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2020</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Kenneth Ain</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Clinical Trials phase II</keyword>
  <keyword>Carcinomas, thyroid</keyword>
  <keyword>Radioiodine-Unresponsive</keyword>
  <keyword>Papillary</keyword>
  <keyword>Follicular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT00287287/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide (Revlimid)</title>
          <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.&#xD;
Lenalidomide: Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide (Revlimid)</title>
          <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.&#xD;
Lenalidomide: Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide (Revlimid)</title>
            <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Percentage of patients who responded to treatment (either stable disease or complete response) based on total tumor volume measurements from CT scans.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <desc>Serious adverse events were defined as Grade 3 or higher.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide (Revlimid)</title>
          <description>Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Ain</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>8593236652</phone>
      <email>kenneth.ain@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

